Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Given Imaging and InScope agreement terminated
Ethicon Endo-Surgery has cited a shift in its strategic priorities within gastroenterology and other areas as the reason for ending the relationship. InScope will pay Given Imaging $7.6
Ethicon Endo-Surgery has cited a shift in its strategic priorities within gastroenterology and other areas as the reason for ending the relationship. InScope will pay Given Imaging $7.6
These cells are made available at the time of surgery using the celution system, an investigational device. In this investigational procedure, a patient’s breast is augmented with her
According to data presented at the American Heart Association’s Scientific Sessions, when compared to nuclear stress – the most frequently used imaging procedure for the assessment of coronary
The open-label follow-up phase lasted nine months, and was the continuation of a three month Phase III double blind controlled trial. This study had demonstrated that Lodotra was
The combination of Healthways’s behavioral support program and GSK Consumer Healthcare’s over-the-counter product alli (orlistat 60mg) for weight control will help thousands of people improve their overall health,
Additional data were presented suggesting that a single treatment with SB-509 may increase the mobilization of stem cells into a subject’s blood. These circulating stem cells may have
The company is collaborating with Prof. Martin Gleave, professor at the department of urological sciences, University of British Columbia and director of the prostate centre at Vancouver General
Under the terms of the agreement, Gilead will pay LGLS a $20 million upfront license payment and royalties on net sales. LGLS also could earn up to $182
C-reactive protein (CRP) level is an important, independent marker of cardiovascular morbidity and mortality. Additionally, the company announced the identification of a genomic biomarker, which may be used
MERLIN TIMI-36 (metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the